09Jan/14

Researchers find comparable long-term outcomes between diastolic and systolic … – Science Codex

Researchers find comparable long-term outcomes between diastolic and systolic
Science Codex
(Boston) – A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long-term outcomes between congestive heart failure patients with preserved ejection fraction commonly known as 
Participation rate problem in rehabStarPhoenix

all 5 news articles »

09Jan/14

Researchers find comparable long-term outcomes between diastolic and systolic … – EurekAlert (press release)

Researchers find comparable long-term outcomes between diastolic and systolic
EurekAlert (press release)
(Boston) – A new study by researchers at Boston University School of Medicine (BUSM) and Boston Medical Center (BMC) found comparable long-term outcomes between congestive heart failure patients with preserved ejection fraction commonly known as 

and more »

09Jan/14

Was hat sich 2013 in der MS-Therapie getan? – AMSEL – Multiple Sklerose … – Multiple Sklerose News: Startseite

Was hat sich 2013 in der MS-Therapie getan? – AMSEL – Multiple Sklerose
Multiple Sklerose News: Startseite
In Phase-III-Studien befinden sich derzeit Daclizumab, Laquinimod, Ocrelizumab, Ofatumumab und auch Rituximab.Für Ofatumumab und Rituximab ergänzte die FDA im September die Produktinformationen um eine Black-Box-Warnung, die auf das Risiko 

and more »

09Jan/14

Was hat sich 2013 in der MS-Therapie getan? – Multiple Sklerose News: Startseite


Multiple Sklerose News: Startseite

Was hat sich 2013 in der MS-Therapie getan?
Multiple Sklerose News: Startseite
In Phase-III-Studien befinden sich derzeit Daclizumab, Laquinimod, Ocrelizumab, Ofatumumab und auch Rituximab.Für Ofatumumab und Rituximab ergänzte die FDA im September die Produktinformationen um eine Black-Box-Warnung, die auf das Risiko 

and more »

09Jan/14

When organ donation relies on Facebook, something is wrong – The Globe and Mail


The Globe and Mail

When organ donation relies on Facebook, something is wrong
The Globe and Mail
That some Canadians are turning to social media in search of donors indicates the troubled state of organ donation in this country. The deceased donation The primary motive for becoming an organ donor is to help someone else. One donor’s generosity 
Website to be launched on Jan 26 to promote organ donationIBNLive

all 3 news articles »

09Jan/14

Lilly Licenses Zymeworks Technology to Develop Bi-specific Antibodies – Genetic Engineering News

Lilly Licenses Zymeworks Technology to Develop Bi-specific Antibodies
Genetic Engineering News
Zymeworks has entered into a worldwide licensing and collaboration agreement with ImClone Systems, a wholly owned subsidiary of Eli Lilly, to develop a number of bi-specific antibody oncology therapeutics using Zymeworks’ Azymetric™ platform.
Zymeworks Announces $15.0 Million Private Placement Financing to Advance The Herald | HeraldOnline.com (press release)
Zymeworks, ImClone Systems partner to develop novel bi-specific antibody News-Medical.net

all 14 news articles »